The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
EFPIA’s vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients.
EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
Our Organisational Structure
EFPIA specialised groups
European Biopharmaceutical Enterprises (EBE) represents the voice of biopharmaceutical companies of all sizes in Europe and is a specialised group within EFPIA. Established in 2000, EBE is recognised as the leading biopharmaceutical association in Europe.
Vaccines Europe (VE) is the specialised vaccine industry group within EFPIA. It represents major innovative research-based global vaccine companies as well as small and medium sized enterprises operating in Europe.
EFPIA Partners in Research
The evolving societal and healthcare challenges as well as opportunities offered by new sciences and technologies, call for a much more integrated health research environment than in the past. Responding to the need for integrated cross-sector collaboration in R&D, EFPIA has created "Partners in Research" as a constituent entity open to companies operating in such associated sectors (imaging, MedTech, diagnostics, animal health, IT including e- and m-technologies, contract research organisations, etc.). This membership status makes it possible to jointly design and implement collaborative R&D initiatives in the framework of the Innovative Medicines Initiatives (the largest public private partnership in health research worldwide), which will ultimately implement new R&D, operational and business models that will benefit all sectors involved (impact on R&D processes), patients (new treatment pathways), and society (incentives for reinvestment in areas where there is market failure).
Partners in Research: implementing technology integration
List of current Partners in Research
For further information about Partners in Research, please contact the Science Policy team at email@example.com.